- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04139070
Electrochemotherapy for Non-curable Gastric Cancer
August 17, 2020 updated by: Zealand University Hospital
This is an explorative, phase I clinical trial.
The aim of this study is to establish the safety and efficacy of electrochemotherapy for non-curable gastric cancer.
Study Overview
Detailed Description
This is an explorative, phase I clinical trial.
Aim of this study is to establish the safety of electrochemotherapy as a palliative treatment for advanced (non-curable) gastric cancer.
The study involves recruitment of 8 patients with histologically verified and non-curable gastric cancer (including Siewert Type II and II).
Patients will be recruited from Department of Surgery, Odense University Hospital and from Zealand University Hospital after their case has been reviewed by the multidisciplinary team (MDT).
Electrochemotherapy will take place at Department of Surgery, Zealand University Hospital.
After the treatment patients will be referred to Odense University Hospital for follow-up.
Electrochemotherapy will be performed as an additive treatment to standard oncological care.
Patients are treated once and will be followed with endoscopy, biopsies, scans, blood samples and questionnaires after 4-6 weeks and 8-12 weeks with a minimum interval of 4 weeks.
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Køge, Denmark, 4600
- Recruiting
- Department of Surgery, Zealand University Hospital
-
Contact:
- Malene Broholm, MD
- Phone Number: +45 41272742
- Email: malea@regionsjaelland.dk
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients must be mentally capable of understanding the information given.
- Patients must give written informed consent.
- Histologically verified gastric cancer (adenocarcinoma, including Siewert Type II and II)
- Non-curable disease according to MDT decision
- Age ≥ 18 years.
- ASA class I-III (Classification of the American Society of Anesthesiology)
- Thrombocytes ≥ 50 billions/l, INR >1,2. Medical correction is allowed, e.g. correction of elevated INR by means of vitamin K or administration of freshly frozen plasma.
- Performance status ECOG/WHO ≤2
Exclusion Criteria:
- Locally advanced non-metastatic EGJ/GC patients that may become resectable after pretreatment
- Inability to perform upper endoscopy with attached equipment.
- Uncorrectable coagulation disorder
- Patients with ICD or pacemaker units
- Myocardial insufficiency, defined as NYHA class >2
- Concurrent treatment with an investigational medicinal product.
- Renal impairment, defined as GFR <40 ml/min
- Pregnancy
- Concurrent inclusion in a medical trial where the intervention may affect safety measures used in the current protocol.
- Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the study recruitments.
- Acute pulmonary infection.
- Medical history of severe pulmonary disease.
- Previous allergic reactions to bleomycin.
- Previous cumulative dose of bleomycin exceeding 250mg/m2.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treátment group
8 patients are expected to be included in this study.
The patients will be treated once with bleomycin in combination with elektroporation
|
Electroporation in combination with systemically administered bleomycin
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of Treatment-Emergent Adverse Events (CTCAE)
Time Frame: 3 months
|
Safety evaluation will be performed via continuous assessment of safety parameters by reviewing events as they arise. The investigation will be put on hold if unacceptable safety issues are outstanding. Adverse Events (AE) and Serious Adverse Events (SAE) will be evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE). |
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Histopathological characterization of tumor biopsies
Time Frame: 3 months
|
Endoscopic biopsies will be collected.
Standard histology (Characterization of tumor tissue, fibrosis) will be performed and regression grade according to current standards
|
3 months
|
Gene expression analysis
Time Frame: 3 months
|
Specific immunohistochemical staining for PD-1/PD-L1, additionally, samples will be stained for CD3, CD8 and CD28.
Finally, gene expression analyses will be performed using the Nano String method.
In this current study, we plan to use the PanCancer IO 360 gene expression panel to analyze mRNA.
This is a - 770-plex gene expression panel covering the complex interplay between tumor, microenvironment and immune response in cancer, including T and B cell activation and inhibition,, adhesion molecules, chemokines and cytokines, and pattern recognition receptors.
This is a predefined gene panel and does not involve extensive mapping of the human genome.
|
3 months
|
Quality of life with "The European Organization for Research and Treatment of Cancer quality of life questionnaire" (EORTC QLQ-C30)
Time Frame: 3 months
|
Quality of Life questionnaires will be collected at baseline and after 8-12 weeks using the EORTC QLQ-C30 questionnaire.
The questionnaire consist of 30 questions with a maximum score of 126 points and a minimum score of 30 points.
|
3 months
|
Tumor volume
Time Frame: 3 months
|
Tumor response will be evaluated through endoscopic ultrasound (EUS) to measure tumor volume before and after treatment
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
June 15, 2020
Primary Completion (ANTICIPATED)
January 1, 2021
Study Completion (ANTICIPATED)
July 1, 2021
Study Registration Dates
First Submitted
October 23, 2019
First Submitted That Met QC Criteria
October 23, 2019
First Posted (ACTUAL)
October 25, 2019
Study Record Updates
Last Update Posted (ACTUAL)
August 20, 2020
Last Update Submitted That Met QC Criteria
August 17, 2020
Last Verified
August 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- REG-033-2019
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Cancer
-
City of Hope Medical CenterRecruitingGastric Cancer | Gastric Adenocarcinoma | Gastric Cancer Stage IV | Gastric Neoplasm | Gastric Cancer Metastatic to Lung | Gastric Cancer Stage | Gastric Cancer Metastatic to Liver | Gastric Cancer Stage III | Gastric Cancer Stage II | Gastric Lesion | Gastric Cancer in Situ | Gastric Cancer Stage IIIB | Gastric... and other conditionsUnited States, Japan
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage 0 Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage II Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IIB Gastric Cancer AJCC v8 | Pathologic Stage... and other conditionsUnited States
-
City of Hope Medical CenterActive, not recruitingAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Diffuse Adenocarcinoma of the Stomach | Intestinal Adenocarcinoma of the Stomach | Mixed Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric Cancer and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGastric Adenocarcinoma | Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage I Gastric Cancer AJCC v8 | Clinical Stage IIA Gastric Cancer AJCC v8 | Clinical Stage IVA Gastric Cancer AJCC v8 | Pathologic Stage IB Gastric Cancer AJCC v8 | Pathologic Stage II Gastric Cancer AJCC v8 | Pathologic... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedGastric Adenocarcinoma | Stage IV Gastric Cancer | Stage II Gastric Cancer | Stage III Gastric CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedGastroesophageal Junction Adenocarcinoma | Gastric Cardia Adenocarcinoma | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage IIIB Gastric Cancer AJCC v7United States
-
National Cancer Institute (NCI)CompletedAdenocarcinoma of the Gastroesophageal Junction | Stage IV Gastric Cancer | Recurrent Gastric Cancer | Adenocarcinoma of the Stomach | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric CancerUnited States
-
National Cancer Institute (NCI)CompletedGastric Cancer | Gastric NeoplasmsUnited States
-
AIO-Studien-gGmbHBristol-Myers SquibbCompletedGastric Cancer | Esophageal Cancer | Adenocarcinoma Gastric | Metastatic Gastric Cancer | GastroEsophageal Cancer | HER2 Positive Gastric CancerGermany
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)RecruitingGastric Adenocarcinoma | Epstein-Barr Virus Positive | Mismatch Repair Protein Deficiency | Stage IB Gastric Cancer AJCC v7 | Stage II Gastric Cancer AJCC v7 | Stage IIA Gastric Cancer AJCC v7 | Stage IIB Gastric Cancer AJCC v7 | Stage III Gastric Cancer AJCC v7 | Stage IIIA Gastric Cancer AJCC v7 | Stage... and other conditionsUnited States
Clinical Trials on Bleomycin
-
Sophie HorbachIGEAUnknownVascular Malformations | Capillary MalformationsNetherlands
-
Jinnah Postgraduate Medical CentreCompletedCutaneous WartsPakistan
-
Oslo University HospitalActive, not recruitingVenous MalformationNorway
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)UnknownMelanoma (Skin)United States
-
South Tees Hospitals NHS Foundation TrustTeesside UniversityRecruitingVascular MalformationsUnited Kingdom
-
Universita di VeronaIGEATerminatedPancreatic CancerItaly
-
Copenhagen University Hospital at HerlevTerminated
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)Completed
-
Inovio PharmaceuticalsCompletedHead and Neck CancerUnited States
-
Ichor Medical Systems IncorporatedNational Cancer Institute (NCI)Withdrawn